arrow
P

Paul C. Roberts

national institutes of health
H指数:31
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Distinct T cell correlates of COVID-19 risk before and after a second booster in previously SARS-CoV-2 infected versus naïve COVAIL trial participants

先前感染SARS-CoV-2与未感染的COVAIL试验参与者在二次加强针前后COVID-19风险的T细胞相关性差异

2026-10-060
OAAI
SARS-CoV-2 variant booster vaccination and infection alter the breadth of the memory B cell repertoire

SARS-CoV-2变异株加强疫苗接种和感染改变记忆B细胞库的广度

2026-06-100
PRE
Effect of Omicron BA.1-based compared to prototype booster mRNA vaccination on incidence of COVID-19 in the COVAIL trial

与原型加强针mRNA疫苗接种相比,Omicron BA.1基线加强针mRNA疫苗接种对COVAIL试验中COVID-19发病率的影響

Vaccine
IF3.5
2025-09-090
OAAI
Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine

使用双价信使核糖核酸严重急性呼吸综合征冠状病毒2疫苗加强接种后的黏膜和系统性抗体应答

2025-04-290
PRE
A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone® or Flublok®) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45 years of age

一项关于两种四价季节性流感疫苗(Fluzone®或Flublok®)在18-45岁健康成年人中,单独使用或与两种佐剂(AF03或Advax-CpG55.2)联合使用时的安全性、反应原性和免疫原性的I期研究

VACCINE
IF3.5
2025-04-010
PRE
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial
2024-09-261
PRE
A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults

一项2期临床试验,用于评估在健康美国成年人中使用和不使用AS03佐剂的2013年和2017 A(H7N9) 灭活流感病毒疫苗的安全性,反应原性和免疫原性

2024-03-274
PRE
Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial
2023-08-2819
OAAI
Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial
2023-08-101
OA
Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
2023-07-1117
OAAI
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial
2023-04-1011
OA
A Multicenter, Controlled Human Infection Study of Influenza A(H1N1)pdm09 in Healthy Adults

健康成人甲型H1N1流感pdm09多中心对照人类感染研究

2023-01-265
OA
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant
2022-07-01126
OAAI
Homologous and Heterologous Covid-19 Booster Vaccinations
2022-03-17399
OAAI
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
2021-01-07560
OAAI
Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
Science
IF45.8
2021-01-010
OAAI